Article
Multidisciplinary Sciences
Apurva Singh, Hannah Horng, Leonid Roshkovan, Joanna K. Weeks, Michelle Hershman, Peter Noel, Jose Marcio Luna, Eric A. Cohen, Lauren Pantalone, Russell T. Shinohara, Joshua M. Bauml, Jeffrey C. Thompson, Charu Aggarwal, Erica L. Carpenter, Sharyn Katz, Despina Kontos
Summary: In this study, we aimed to determine the feasibility of a novel radiomic biomarker that can predict progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients undergoing immunotherapy. We analyzed data from 107 NSCLC patients treated with pembrolizumab-based therapy and used various software and techniques to extract radiomic features and harmonize the data. Our findings suggest that the integration of radiomic phenotypes with clinical factors improves the prediction of PFS in these patients.
SCIENTIFIC REPORTS
(2022)
Article
Genetics & Heredity
Liam F. Spurr, Ralph R. Weichselbaum, Sean P. Pitroda
Summary: This study demonstrates that tumor aneuploidy could serve as an independent prognostic indicator in patients with low tumor mutational burden (TMB) receiving immunotherapy.
Article
Oncology
Xiaohong Xie, Liqiang Wang, Xinni Wang, Wan-Hung Fan, Yinyin Qin, Xinqing Lin, Zhanhong Xie, Ming Liu, Ming Ouyang, Shiyue Li, Chengzhi Zhou
Summary: The study indicates that cell surface vimentin (CSV) positive circulating tumor cells (CTCs) can serve as diagnostic biomarkers for lung cancer, showing correlations with clinicopathological characteristics of lung cancer patients and demonstrating better diagnostic performance compared to serum tumor markers.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Alexia Monastirioti, Chara Papadaki, Konstantinos Rounis, Despoina Kalapanida, Dimitrios Mavroudis, Sofia Agelaki
Summary: The study revealed that high expression of miR-202 in non-small cell lung cancer patients is associated with disease progression, shorter progression-free survival, and overall survival. In subgroup analysis, miR-202 and miR-26a expression had different impacts on overall survival in squamous and non-squamous subgroups. These findings suggest that circulating miRNAs may serve as potential biomarkers in NSCLC patients.
Article
Oncology
Arlou Kristina Angeles, Petros Christopoulos, Zhao Yuan, Simone Bauer, Florian Janke, Simon John Ogrodnik, Martin Reck, Matthias Schlesner, Michael Meister, Marc A. Schneider, Steffen Dietz, Albrecht Stenzinger, Michael Thomas, Holger Sultmann
Summary: This study utilized various sequencing technologies to analyze plasma DNA from 43 ALK+ NSCLC patients receiving ALK-directed therapies, finding that 51% of these patients had ALK-related alterations. Evidence for early detection of disease progression is crucial for guiding patient management and therapy decisions.
NPJ PRECISION ONCOLOGY
(2021)
Article
Oncology
Jie Zhang, Yang Hong, Liang Wang, Weiheng Hu, Guangming Tian, Di Wu, Yang Wang, Ling Dai, Ziran Zhang, Yue Yang, Jian Fang
Summary: This study aimed to detect and describe the distribution characteristics of circulating tumor cells (CTCs) and circulating tumor-derived endothelial cells (CTECs) in patients with advanced lung cancer, and explore the correlation between CTC/CTEC subtypes and novel prognostic biomarkers. CTCs and CTECs derived from 52 patients with advanced lung cancer were identified using the subtraction enrichment-immunofluorescence in situ hybridization (SE-iFISH) system.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biology
Qingzhu Jia, Qian Chu, Anmei Zhang, Jing Yu, Fangfang Liu, Kaiyu Qian, Yu Xiao, Xue Wang, Ying Yang, Yi Zhao, Ji He, Guanghui Li, Yisong Y. Wan, Conghua Xie, Bo Zhu
Summary: The study used whole exome sequencing to investigate the impact of tumor mutational burden (TMB) and chromosomal aneuploidy (ANE) on the survival outcomes of non-small cell lung cancer patients undergoing radiotherapy. Higher TMB and lower ANE were associated with better survival outcomes, and these factors were found to interact synergistically.
COMMUNICATIONS BIOLOGY
(2021)
Article
Hematology
Shayu Deshpande, Ruslana G. Tytarenko, Yan Wang, Eileen M. Boyle, Cody Ashby, Carolina D. Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Fenghuang Zhan, Faith E. Davies, Gareth J. Morgan, Frits van Rhee, Brian A. Walker
Summary: This study found that cfDNA levels could distinguish MM patients into high-risk and low-risk groups, with higher levels associated with poorer clinical outcomes. ctDNA correlated strongly with GEP70 risk score, showing a spike after chemotherapy along with increased KRAS mutation allele fraction. Monitoring cfDNA levels may serve as a dynamic tool to capture genetic events in MM.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Xiu-Yan Huang, Feng Li, Ting-Ting Li, Jun-Tao Zhang, Xiang-Jun Shi, Xin-Yu Huang, Jian Zhou, Zhao-You Tang, Zi-Li Huang
Summary: This study developed a CTC detection system using EpCAM/vimentin/GPC3 antibody-modified lipid magnetic spheres (LMS) to capture tumor cells with different phenotypes. The system showed high specificity, sensitivity, and capture efficiency in vitro and was able to predict tumor progression in vivo and in clinical settings.
JOURNAL OF NANOBIOTECHNOLOGY
(2023)
Article
Oncology
Xiao-Ran Liu, Jian-Jun Yu, Guo-Hong Song, Li-Jun Di, Han-Fang Jiang, Ying Yan, Xu Liang, Ru-Yan Zhang, Ran Ran, Jing Wang, Han Bai, Shi-Dong Jia, Hui-Ping Li
Summary: In this study, it was found that high pCTL levels were associated with shorter PFS and FGFR1 mutation in HER2+ advanced breast cancer patients. The study did not find a predictive role of pCTL in HR-positive and TNBC patients. High pCTL levels were also associated with immune suppressive indicators.
Article
Oncology
Rafal Dziadziuszko, Solange Peters, Tony Mok, D. Ross Camidge, Shirish M. Gadgeel, Sai-Hong Ignatius Ou, Krzysztof Konopa, Johannes Noe, Malgorzata Nowicka, Walter Bordogna, Peter N. Morcos, Vlatka Smoljanovic, Alice T. Shaw
Summary: We retrospectively analyzed data from the phase III ALEX study to assess the prognostic value of circulating cell-free DNA (cfDNA) in treatment-naive, advanced ALK+ non-small cell lung cancer (NSCLC) patients. We found a positive correlation between cfDNA concentration and tumor characteristics. Patients with higher cfDNA concentration were more likely to experience disease progression, and alectinib showed longer progression-free survival compared to crizotinib.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Peey-Sei Kok, Kirsty Lee, Sally Lord, Thomas John, Ian Marschner, Yi-Long Wu, Tony S. K. Mok, Chen Khoon Lee
Summary: This study explored the feasibility of incorporating circulating tumor DNA (ctDNA) into the Response Evaluation Criteria in Solid Tumors (RECIST) to provide a more reliable measurement of tumor response. The study found that in patients with EGFR-mutant NSCLC, the absence of detectable ctDNA at week 8 was correlated with improved survival.
Article
Oncology
Alexcia C. Braun, Fernando A. B. Campos, Emne A. Abdallah, Anna P. C. Ruano, Tiago da S. Medina, Milena S. Tariki, Fabio F. E. Pinto, Celso A. L. de Mello, Ludmilla T. D. Chinen
Summary: Desmoid tumors are rare neoplasms with high recurrence rates, composed of fibroblastic cells expressing key molecules. Circulating tumor cells (CTCs) in the blood could serve as early biomarkers for invasion and dissemination. This study found a high prevalence of CTCs in DT patients and showed concordance in beta-catenin expression between CTCs and primary tumors, suggesting new avenues for studying DT biology and predicting disease dynamics.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yuichi Kumaki, Steve Olsen, Mitsukuni Suenaga, Tsuyoshi Nakagawa, Hiroyuki Uetake, Sadakatsu Ikeda
Summary: This study describes a method to distinguish focal and non-focal MET amplification in advanced cancer patients using comprehensive genomic profiling of cfDNA. Focal MET amplification accounted for around 30% of all MET amplification, found in 3.7% of patients with diverse cancers and associated with a higher plasma copy number. Further clinical studies are needed to evaluate the clinical utility of targeted therapies for tumors with focal MET amplification detected by NGS of cfDNA.
Article
Oncology
Gehan Botrus, Pedro Luiz Serrano Uson Junior, Puneet Raman, Adrienne E. Kaufman, Heidi Kosiorek, Jun Yin, Yu Fu, Umair Majeed, Mohamad Bassam Sonbol, Daniel H. Ahn, Isabela W. Chang, Leylah M. Drusbosky, Hiba Dada, Jason Starr, Mitesh Borad, Kabir Mody, Tanios S. Bekaii-Saab
Summary: Detection of ctDNA in advanced PC at initial diagnosis can predict clinical outcomes. Patients with >= 2 detectable genomic alterations have worse survival rates. Patients with KRAS and TP53 alterations are associated with worse survival rates.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Yue Zhao, Jiahui Li, Dai Li, Zhefang Wang, Jiangang Zhao, Xiaolin Wu, Qiye Sun, Peter Ping Lin, Patrick Plum, Alexander Damanakis, Florian Gebauer, Menglong Zhou, Zhen Zhang, Hans Schloesser, Karl-Walter Jauch, Peter J. Nelson, Christiane J. Bruns
SEMINARS IN CANCER BIOLOGY
(2020)
Article
Oncology
Lina Zhang, Xinyong Zhang, Yanxia Liu, Tongmei Zhang, Ziyu Wang, Meng Gu, Yilin Li, Daisy Dandan Wang, Weiying Li, Peter Ping Lin
Review
Cell Biology
Peter Ping Lin
Review
Chemistry, Analytical
Jie Cheng, Yang Liu, Yang Zhao, Lina Zhang, Lingqian Zhang, Haiyang Mao, Chengjun Huang
Article
Oncology
Yang Hong, Jiahui Si, Jie Zhang, Ying Xiong, Jianzhi Zhang, Peter Ping Lin, Jian Fang, Yue Yang, Chao Lv, Yuanyuan Ma
Summary: This study investigated the distribution and clinical significance of circulating aneuploid cells (CACs) in resectable non-small cell lung cancer (NSCLC) patients. The pre-surgery small cell size CACs, especially the triploid subtype, could be regarded as a potential prognostic biomarker for patients with resectable NSCLC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Tongmei Zhang, Lina Zhang, Yuan Gao, Ying Wang, Yanxia Liu, Hongmei Zhang, Qunhui Wang, Fanbin Hu, Jie Li, Jinjing Tan, Daisy Dandan Wang, Olivier Gires, Peter Ping Lin, Baolan Li
Summary: Longitudinal monitoring and early detection of treatment resistance in cancer patients undergoing anti-angiogenic therapy is challenging. This study found that baseline Vim(+) CTECs and post-therapeutic EpCAM(+) CTCs and CTECs can serve as predictive biomarkers for monitoring response to anti-angiogenesis combination regimens in NSCLC patients.
MOLECULAR ONCOLOGY
(2021)
Article
Oncology
Yang Chen, Yanyan Li, Changsong Qi, Cheng Zhang, Dan Liu, Youping Deng, Yuanyuan Fu, Vedbar S. Khadka, Daisy Dandan Wang, Shanyang Tan, Shujun Liu, Zhi Peng, Jifang Gong, Peter Ping Lin, Xiaotian Zhang, Jian Li, Yilin Li, Lin Shen
Summary: This study revealed that heterogeneous-sized CTCs in gastric cancer patients are associated with poor treatment response and prognosis. Small and large CTCs showed distinct gene variations, indicating different mechanisms of therapy resistance.
Article
Oncology
Alexander Y. Lin, Daisy Dandan Wang, Linda Li, Peter Ping Lin
Summary: This study aims to develop a strategy to effectively distinguish and co-detect viable and dead non-hematological cancer cells, which will assist in evaluating therapeutic effects and monitoring treatment resistance.
Article
Immunology
Yanxia Liu, Tongmei Zhang, Lina Zhang, Cong Zhao, Zhiyun Zhang, Ziyu Wang, Meng Gu, Weiying Li, Baolan Li
Summary: Combined application of bevacizumab and anti-PD-1 antibody can effectively treat advanced non-small-cell lung cancer by increasing the infiltration and cytotoxic function of CD8(+) T cells, as demonstrated in both mouse models and a patient.
Article
Chemistry, Analytical
Xiaofeng Luan, Yuang Li, Haiping Zhao, Sheng Sun, Yuanyuan Fan, Wenchang Zhang, Lingqian Zhang, Mingxiao Li, Jinghui Wang, Tian Zhi, Lina Zhang, Yang Zhao, Chengjun Huang
Summary: This study proposes a toolchain for enriching and proliferating single cells from pleural effusions and characterizing their adherent morphologies and suspended electrical properties. The results reveal a significant correlation between the adherent morphology and suspended electrical properties of single cells.
SENSORS AND ACTUATORS B-CHEMICAL
(2022)
Article
Engineering, Biomedical
Jie Cheng, Lina Zhang, Yiran Zhang, Yifei Ye, Wenjie Zhao, Lingqian Zhang, Yuang Li, Yang Liu, Wenchang Zhang, Hongyan Guo, Mingxiao Li, Yang Zhao, Chengjun Huang
Summary: In this paper, a three-dimensional sieving method for rare tumor cell enrichment was proposed. It effectively eliminated dead zones in traditional two-dimensional cell filters, resulting in high throughput and recovery rates. The method was able to effectively enrich rare target cells from pleural effusion samples and the purified cells exhibited significantly stronger proliferation capabilities compared to unprocessed cells.
BIO-DESIGN AND MANUFACTURING
(2022)
Review
Oncology
Hongyan Cheng, Shang Wang, Wenqing Luan, Xue Ye, Sha Dou, Zhijian Tang, Honglan Zhu, Peter Ping Lin, Yi Li, Heng Cui, Xiaohong Chang
Summary: The study aimed to detect CTCs and CTECs in OC patients using SE-iFISH method, revealing high detection rate of CTCs and their diagnostic value. CTC counts were significantly higher in OC group compared to benign group, with subclass characteristics analysis contributing to a deeper understanding of OC mechanism.
CHINESE JOURNAL OF CANCER RESEARCH
(2021)